Skip to main content

Table 3 Patient characteristics at baseline

From: The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data

Variable Asia Africa South America a Overall
N 434 (4.77%) 8635 (94.83%) 37 (0.41%) 9106
Study period 2005-2009 1999-2012 2000-2004 1999-2012
Gender     
Female 38.7% [168/434] 47.0% [4,060/8,635] 18.9% [7/37] 46.5% [4,235/9,106]
Age     
Median age [IQR, range] in years 17 [8-28,0.6-80] 3 [1.7-5,0-80] 20 [16-25,8-58] 3 [1.8-6, 0-80]
<1 y 0.2% [1/434] 9.1% [782/8,635] 0.0% [0/37] 8.6% [783/9,106]
1 to <5 y 7.8% [34/434] 65.1% [5,619/8,635] 0% [0/37] 62.1% [5,653/9,106]
5 to <12 y 25.3% [110/434] 16.5% [1,421/8,635] 10.8% [4/37] 16.9% [1,535/9,106]
≥12 y 66.6% [289/434] 9.4% [813/8,635] 89.2% [33/37] 12.5% [1,135/9,106]
Treatment supervision b     
Full 67.3% [292/434] 95.1% [8,212/8,635] 100.0% [37/37] 93.8% [8,541/9,106]
Partial 32.7% [142/434] 4.9% [423/8,635] 0.0% [0/37] 6.2% [565/9,106]
Drug formulation     
Fixed dose combination (FDC) 78.6% [341/434] 44.0% [3,797/8,635] 0.0% [0/37] 45.4% [4,138/9,106]
Co-blistered non-fixed dose combination (co-blistered NFDC) 0.0% [0/434] 14.6% [1,257/8,635] 0.0% [0/37] 13.8% [1,257/9,106]
Loose non-fixed dose combination: target dose 25 mg/kg (loose NFDC-25) 0.0% [0/434] 15.0% [1,293/8,635] 0.0% [0/37] 14.2% [1,293/9,106]
Loose non-fixed dose combination: target dose 30 mg/kg (loose NFDC-30) 21.4% [93/434] 26.5% [2,288/8,635] 100.0% [37/37] 26.6% [2,418/9,106]
Enrolment clinical variables     
Geometric mean parasitemia [95% CI] in parasites/μl 8,504 [7,409-9,761] 19,508 [18,944-20,089] 80 [55-116] 18,338 [17,801-18,891]
Median weight [IQR, range] in kg 40 [20-50,7-72] 12 [10-17, 5-104] 59 [47-65,24-80] 12.7 [10-18, 5-104]
Underweight for agec 37.1% [13/35] 20.6% [1,248/5,821] - 20.7% [1,297/6,269]
Anemic (hb < 10 g/dl)d 34.3% [149/434] 59% [3,754/5,821] 13.5% [5/37] 56.6% [3,908/6,906]
Gametocytes presencee 39.4% [56/142] 10.0% [462/5,821] 24.3% [9/37] 11.0% [527/4,796]
Fever (temp > 37.5 °C) 77.7% [227/292] 66.4% [5,769/5,821] 16.2% [6/37] 68.5% [6,002/8,766]
Hemoglobin [mean ± SD] in g/dl 10.9 ± 2.29 9.5 ± 2.06 12.06 ± 1.93 9.6 ± 2.11
  1. aSingle study from Columbia.
  2. bTreatment supervision: The treatment was fully supervised if each dose of the three-day regimen was administered by a nurse/or any other medical staff. The treatment was partially supervised if only the dose on the first day was administered by medical staff, the dose on day 2 and day 3 being self-administered by the patients or the parents/guardians.
  3. cDefined using a weight-for-age score (WAZ) < -2 in children <5 years of age. WAZ scores outside the range (-6.6) were treated as outliers.
  4. dAsia v Africa (P = 0.005), Asia v South America (P = 0.438) and Africa v South America (P = 0.042).
  5. eAsia v Africa (P < 0.001), Asia v South America (P = 0.236) and Africa v South America (P = 0.308).